- Trials with a EudraCT protocol (1)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1 result(s) found for: 2022-000836-49.
Displaying page 1 of 1.
EudraCT Number: 2022-000836-49 | Sponsor Protocol Number: MK-3475-D46 | Start Date*: 2023-01-16 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-... | |||||||||||||
Medical condition: First-line treatment of metastatic programmed cell death ligand 1 expressing (tumor proportion score ≥50%) non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) GR (Trial now transitioned) LT (Trial now transitioned) IT (Trial now transitioned) LV (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
